Document ID: chunk:federal_register_of_legislation:F2024C01086:clause:1_15918
Version: federal_register_of_legislation:F2024C01086
Segment Type: clause
Provision Reference: sch 1 cl 15918
Character Range: 934334–936875

15918                                                 Megavoltage planning—level 4                                                                                                                                                                                                                                                                                                             6,676.00
                                                      Intracranial stereotactic radiation therapy (SRT) simulation and dosimetry for treatment planning, if:
                                                      (a) all of the following apply in relation to the simulation:
                                                      (i) treatment set‑up and technique specifications are in preparation for multiple non‑coplanar, rotational or fixed beam stereotactic delivery;
                                                      (ii) precise personalised patient set‑up and immobilisation techniques are suitable for reliable imaging acquisition and reproducible SRT small‑field and ablative treatments;
                                                      (iii) a high‑quality three‑dimensional image volume dataset is acquired in treatment position for the intracranial lesions to be planned and treated and verified; and
                                                      (b) all of the following apply in relation to the dosimetry:
                                                      (i) the planning process is required to calculate dose to single or multiple target structures and requires a dose‑volume histogram to complete the planning process;
                                                      (ii) based on review and assessment by a radiation oncologist, the planning process maximises the differential between target dose, organs at risk and normal tissue dose;
                                                      (iii) all relevant gross tumour volumes, clinical target volumes, planning target volumes and organs at risk are rendered and nominated with planning dose objectives;
                                                      (iv) organs at risk are nominated as planning dose constraints;
                                                      (v) dose calculations and dose‑volume histograms are generated using a validated stereotactic‑type algorithm, with prescription and plan details approved and recorded with the plan
                                                      Applicable once per course of treatment